Treatment outcome and prognosis of patients with stage I-II nasal-type natural killer/T-cell lymphoma receiving induction chemotherapy with GELOX regimen and radical radiotherapy
Li Yiyang,Niu Shaoqing,Wen Ge,Wang Qiaoxuan,Wang Hanyu,Feng Lingling,Xia Yunfei,Zhang Yujing
Department of Radiation Oncology,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in Southern China,Collaborative Innovation Center for Cancer Medicine,Guangzhou 510060,China (Li YY,Wang QX,Wang HY,Feng LL,Xia YF,Zhang YJ);Department of Radiation Oncology,First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080,China (Niu SHQ);Department of Radiation Oncology,Third Affiliated Hospital,Sun Yat-sen University,Guangzhou 510150,China (Wen G)Zhang Yujing,Email:zhangyj@sysucc.org.cn
Abstract：Objective To investigate the treatment outcome and prognostic factors in patients with early-stage extranodal nasal-type natural killer/T-cell lymphoma (ENKTL) who underwent chemotherapy with GELOX (gemcitabine,oxaliplatin,and L-asparaginase) regimen combined with radiotherapy. Methods The clinical data of 74 patients with stage IE-IIE ENKTL who were admitted from 2007 to 2013 were analyzed retrospectively,and based on the chemoradiotherapy regimen and whether they underwent radiotherapy,these patients were divided into three groups. The 47 patients in group A received the preferred chemotherapy with GELOX regimen and then radical radiotherapy;the 10 patients in group B received another regimen at first,then received GELOX as the rescue chemotherapy,and underwent radiotherapy;the 17 patients in group C underwent the chemotherapy with GELOX regimen and did not receive radiotherapy. The median number of cycles of chemotherapy was 3,and the median dose of radiotherapy was 54.6 Gy in 20-30 fractions. Results The complete response (CR) rate after chemotherapy was 34% and the CR rate after radiotherapy was 90%.The 2-year overall survival (OS) and progression-free survival (PFS) rates were 88% and 79%,respectively. The CR rate and 2-year OS and PFS rates for group A+C were 73%,92%,and 84%,respectively. Group A had significantly higher OS and PFS than group B and group C (96%/84% vs. 50%/45% and 47%/40%;all P<0.05).The univariate analysis showed that elevated lactate dehydrogenase level and no response after chemotherapy were the adverse prognostic factors for OS and PFS,and extensive local invasion was the adverse prognostic factor for OS.The multivariate prognostic analysis indicated that no response after chemotherapy was the adverse prognostic factor for OS and PFS. Conclusions The patients with early-stage ENKTL can achieve a good outcome after induction chemotherapy with GELOX regimen combined with radical radiotherapy,but this regimen has no ideal efficacy when applied alone or as rescue chemotherapy.
Li Yiyang,Niu Shaoqing,Wen Ge et al. Treatment outcome and prognosis of patients with stage I-II nasal-type natural killer/T-cell lymphoma receiving induction chemotherapy with GELOX regimen and radical radiotherapy[J]. Chinese Journal of Radiation Oncology, 2016, 25(2): 140-145.
[1]Chan JK,Quintanilla-Martinez L,Ferry JA,et al. Extranodal NK/T-cell lymphoma,nasal type[A]//Swerdlow SH,Campo E,Harris NL,et al. WHO classification of tumours of haematopoietic and lymphoid tissues[M].Lyon:IARC,2008:285-288. [2]Kohrt H,Lee M,Advani R.Risk stratification in extranodal natural killer/T-cell lymphoma[J].Expert Rev Anticancer Ther,2010,10(9):1395-1405.DOI:10.1586/era.10.130. [3]张玉晶,胡伟汉,刘慧,等.鼻型NK/T细胞淋巴瘤的临床和预后分析[J].中华肿瘤杂志,2006,28(1):50-53.DOI:10.3760/j.issn:0253-3766.2006.01.014. Zhang YJ,Hu WH,Liu H,et al. Clinical features and prognosis of nasal type NK/T cell lymphoma[J].Chin J Oncol,2006,28(1):50-53.DOI:10.3760/j.issn:0253-3766.2006.01.014. [4]Li YX,Yao B,Jin J,et al. Radiotherapy as primary treatment for stage ⅠE and ⅡE nasal natural killer/T-cell lymphoma[J].J Clin Oncol,2006,24(1):181-189.DOI:10.1200/JCO.2005.03.2573. [5]金晶,李晔雄,姚波,等.IE~ⅡE期鼻腔NK/T细胞淋巴瘤的放疗效果分析[J].中华放射肿瘤学杂志,2006,15(2):108-113.DOI:10.3760/j.issn:1004-4221.2006.02.009. Jin J,Li YX,Yao B,et al. Outcome of radiotherapy for localized Stage ⅠE and ⅡE nasal NK/T cell lymphoma[J].Chin J Radiat Oncol,2006,15(2):108-113.DOI:10.3760/j.issn:1004-4221.2006.02.009. [6]Tham IWK,Lee KM,Yap SP,et al. Outcome of patients with nasal natural killer (NK)/T-cell lymphoma treated with radiotherapy,with or without chemotherapy[J].Head Neck,2006,28(2):126-134.DOI:10.1002/hed.20314. [7]杨勇,张玉晶,林旭滨,等.放疗在早期鼻型NK/T细胞淋巴瘤综合治疗中作用及预后分析[J].中华放射肿瘤学杂志,2009,18(4):285-289.DOI:10.3760/cma.j.issn.1004-4221.2009.04.285. Yang Y,Zhang YJ,Lin XB,et al. Role of radiotherapy in the combined treatment of patients with early stage extranodal nasal type NK/T-cell lymphoma and analysis of prognostic factors[J].Chin J Radiat Oncol,2009,18(4):285-289.DOI:10.3760/cma.j.issn.1004-4221.2009.04.285. [8]Wang L,Wang ZH,Chen XQ,et al. First-line combination of gemcitabine,oxaliplatin,and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage ⅠE/ⅡE extranodal natural killer/T-cell lymphoma.[J].Cancer,2013,119(2):348-355.DOI:10.1002/cncr.27752. [9]Wang L,Wang WD,Xia ZJ,et al. Combination of gemcitabine,L-asparaginase,and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage ⅠE/ⅡE extranodal natural killer/T cell lymphoma:a retrospective study in a cohort of 227 patients with long-term follow-up[J].Med Oncol,2014,31(3):860.DOI:10.1007/s12032-014-0860-4. [10]Wang BY,Li XQ,Ma XJ,et al. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma,nasal type[J].Am J Hematol,2008,83(10):795-799.DOI:10.1002/ajh.21256. [11]Kim WS,Song SY,Ahn YC,et al. CHOP followed by involved field radiation:is it optimal for localized nasal natural killer/T-cell lymphoma?[J].Ann Oncol,2001,12(3):349-352.DOI:10.1023/A:1011144911781. [12]Wang BY,Lu JJ,Ma XJ,et al. Combined chemotherapy and external beam radiation for stage ⅠE and ⅡE natural killer T-cell lymphoma of nasal cavity[J].Leuk Lymphoma,2007,48(2):396-402.DOI:10.1080/10428190601059795. [13]Kim BS,Kim TY,Kim CW,et al. Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy:result of chemotherapy in NK/T-cell lymphoma[J].Acta Oncol,2003,42(7):779-783.DOI:10.1080/02841860310010682. [14]Huang HQ,Lin ZX,Lin XB,et al. Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide,prednisone,vincristine,cyclophosphamide,and doxorubicin regimen:a single-institution experience[J].Leuk Lymphoma,2011,52(6):1041-1048.DOI:10.3109/10428194.2011.561388. [15]Yong WB,Zheng W,Zhu J,et al. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma,nasal type[J].Ann Hematol,2009,88(7):647-652.DOI:10.1007/s00277-008-0669-3. [16]Jiang M,Zhang H,Jiang Y,et al. Phase 2 trial of"sandwich" L-asparaginase,vincristine,and prednisone chemotherapy with radiotherapy in newly diagnosed,stage ⅠE to ⅡE,nasal type,extranodal natural killer/T-cell lymphoma[J].Cancer,2012,118(13):3294-3301.DOI:10.1002/cncr.26629. [17]Zhou ZY,Li X,Chen CY,et al. Effectiveness of gemcitabine,pegaspargase,cisplatin,and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma:a retrospective study of 17 patients[J].Ann Hematol,2014,93(11):1889-1894.DOI:10.1007/s00277-014-2136-7. [18]牛绍清,张玉晶,温戈,等.早期原发鼻腔NK/T细胞淋巴瘤局部扩大野IMRT前瞻性Ⅱ期研究的初步结果[J].中华放射肿瘤学杂志,2015,24(4):377-381.DOI:10.3760/cma.j.issn.1004-4221.2015.04.006. Niu SQ,Zhang YJ,Wen G,et al. Preliminary results of a phase Ⅱ prospective clinical study of early-stage nasal NK/T-cell lymphoma with extended involved-field intensity-modulated radiotherapy[J].Chin J Radiat Oncol,2015,24(4):377-381.DOI:10.3760/cma.j.issn.1004-4221.2015.04.006. [19]Zang J,Li C,Luo SQ,et al. Early radiotherapy has an essential role for improving survival in patients with stage Ⅰ-Ⅱ nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy-a single institution experience[J].Ann Hematol,2015,94(4):583-591.DOI:10.1007/s00277-014-2244-4.
2016, Vol. 25 
